Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 12, 2004, Pages 4240-4246

  He, Yu Guang ^a   Mayhew, Elizabeth ^a   Mellon, Jessamee ^a   Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM; CISPLATIN; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2 RECEPTOR; THYMIDINE;

APOPTOSIS; ARTICLE; CANCER SUSCEPTIBILITY; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; HUMAN; HUMAN CELL; LYMPHOCYTIC INFILTRATION; MELANOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; MELANOMA; RECEPTORS, INTERLEUKIN-15; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; UVEAL NEOPLASMS;

EID: 9444240454     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0599     Document Type: Article

References (44)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239-251.
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:956-961.
3. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer. 1993;71:2299-2305.
4. Donoso LA, Berd D, Augsburger JJ, Mastrangelo MJ, Shields JA. Metastatic uveal melanoma: pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol. 1985;103:796-798.
5. Char DH. Metastatic choroidal melanoma. Am J Ophthalmol. 1978;86:76-80.
6. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334-336.
7. Niederkorn JY. Immunoregulation of intraocular tumours. Eye. 1997;11:249-254.
8. Niederkorn JY. Immunology of uveal melanoma: immunosuppressive factors and the basis for immunotherapy. In: Albert DM, Polans A, eds. Ocular Oncology. New York: Marcel Dekker, Inc.; 2003:255-268.
9. de la Cruz PO Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112-115.
10. Whelchel JC, Farah SE, McLean FW, Burnier MN. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993;34:2603-2606.
11. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414-1421.
12. Alileche A, Plaisance S, Han DS, et al. Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene. 1993;8:1791-1796.
13. Plaisance S, Rubinstein E, Alileche A, et al. Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer. 1993;55:164-170.
14. Garcia de Galdeano A, Boyano MD, Smith-Zubiaga I, Canavate ML. B16F10 murine melanoma cells express interleukin-2 and a functional interleukin-2 receptor. Tumour Biol. 1996;17:155-167.
15. Boyano MD, Garcia de Galdeano A, Smith-Zubiaga I, Canavate ML. IL-2 treatment of B16F10 melanoma cells stimulates metastatic colonization in the liver. Anticancer Res. 1997;17:1135-1141.
16. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-78.
17. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood. 2000;95:610-618.
18. Barzegar C, Meazza R, Pereno R, et al. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene. 1998;16:2503-2512.
19. Huang XQ, Mitchell MS, Liggett PE, Murphree AL, Kan-Mitchell J. Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol immunother. 1994;38:399-405.
20. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci. 1989;30:829-834.
21. Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer. 1997;73:470-478.
22. de Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, Jager MJ. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1996;234:34-42.
23. Albert DM, Ruzzo MA, McLaughlin MA, et al. Establishment of cell lines of uveal melanoma: methodology and characteristics. Invest Ophthalmol Vis Sci. 1984;25:1284-1299.
24. Luyten GP, van der Spek CW, Brand I, et al. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines. Melanoma Res. 1998;8:11-16.
25. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol. 2000;165:710-715.
26. Ren DH, Mayhew E, Hay C, et al. Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. Invest Ophthalmol Vis Sci. 2004;45:1162-1168.
27. Ma D, Niederkorn JY. Transforming growth factor-beta downregulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology. 1995;86:263-269.
28. Ma D, Luyten GP, Luider TM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci. 1995;36:435-441.
29. Zamai L, Ahmad M, Bennett IM, et al. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188:2375-2380.
30. Screpanti V, Wallin RP, Ljunggren HG, Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol. 2001;167:2068-2073.
31. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665-1670.
32. Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026.
33. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990;40:2353-2362.
34. Wang S, Boonman ZF, Li HC, et al. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol. 2003;171:2789-2796.
35. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254-265.
36. O'Farrelly C, Crispe IN. Prometheus through the looking glass: reflections on the hepatic immune system. Immunol Today. 1999;20:394-398.
37. Nitta T, Oksenberg JR, Rao NA, Steinman L. Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. Science. 1990;249:672-674.
38. Niederkorn JY. Natural killer cells and uveal melanoma. In: Zierhut M, Jager MJ, Ksander B, eds. Immunology of Intraocular Tumors. Lisse, The Netherlands: Swets and Zeitlinger; 2002:73-82.
39. Blom DJ, Luyten GP, Mooy C, et al. Human leukocyte antigen class I expression: marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997;38:1865-1872.
40. Ericsson C, Seregard S, Bartolazzi A, et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:2153-2156.
41. Gombos DS, Mieler WF. Therapy of uveal melanoma: methods and risk factors associated with treatment. In: Polans A, Albert DM, eds. Ocular Oncology. New York: Marcel Dekker, Inc.; 2003;321-352.
42. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 1999;96:7462-7466.
43. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21:283-293.
44. Herbort CP, de Smet MD, Roberge FG, et al. Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40. Transplantation. 1991;52:470-474.